Lu Minfeng, Zhang Shenfeng, Zhang Longqin
Department of Neurology, Haining Hospital of Traditional Chinese Medicine Haining, Jiaxing 314400, Zhejiang, China.
Am J Transl Res. 2025 Apr 15;17(4):3119-3130. doi: 10.62347/PEJW5162. eCollection 2025.
To evaluate the efficacy and safety of Danhong injection combined with dual antiplatelet therapy (DAPT) in patients with acute ischemic stroke (AIS).
A retrospective analysis was conducted on 110 AIS patients (aged 40-80 years, National Institutes of Health Stroke Scale 3-15) admitted between October 2021 and October 2023. Patients were divided into two groups: the intervention group (n=55) received Danhong injection (40 mL/day for 14 days) plus DAPT (aspirin 100 mg + clopidogrel 75 mg), while the control group (n=55) received DAPT alone. Primary outcomes included neurological function, infarct volume, and inflammatory/hemorheological markers. Safety was also assessed.
The intervention group showed greater neurological improvement, with NIHSS scores decreasing from 8.2 to 3.2 compared to 8.5 to 5.1 in the control group (P<0.001). Functional independence rate was higher in the intervention group (81.8% vs. 54.5%, P=0.002). Infarct volume reduction was more pronounced in the intervention group (5.0 cm vs. 6.5 cm at 1 month, P=0.003). Inflammatory markers (C-reactive protein, procalcitonin and neutrophil count) and hemorheological measurements (plasma viscosity, whole-blood viscosity) improved significantly (all P<0.05). No severe adverse events were reported.
Danhong injection combined with DAPT significantly enhanced neurological recovery, reduced infarct volume, and modulated systemic inflammation in AIS patients, with a favorable safety profile.
评估丹红注射液联合双重抗血小板治疗（DAPT）对急性缺血性脑卒中（AIS）患者的疗效和安全性。
对2021年10月至2023年10月收治的110例AIS患者（年龄40 - 80岁，美国国立卫生研究院卒中量表评分3 - 15分）进行回顾性分析。患者分为两组：干预组（n = 55）接受丹红注射液（40 mL/天，共14天）加DAPT（阿司匹林100 mg + 氯吡格雷75 mg），而对照组（n = 55）仅接受DAPT。主要结局包括神经功能、梗死体积以及炎症/血液流变学指标。同时评估安全性。
干预组神经功能改善更明显，美国国立卫生研究院卒中量表评分从8.2降至3.2，而对照组从8.5降至5.1（P < 0.001）。干预组的功能独立率更高（81.8%对54.5%，P = 0.002）。干预组梗死体积缩小更显著（1个月时分别为5.0 cm和6.5 cm，P = 0.003）。炎症指标（C反应蛋白、降钙素原和中性粒细胞计数）以及血液流变学指标（血浆黏度、全血黏度）均显著改善（均P < 0.05）。未报告严重不良事件。
丹红注射液联合DAPT可显著促进AIS患者神经功能恢复，减少梗死体积，并调节全身炎症反应，且安全性良好。
